News
Lilly's Mounjaro demonstrates cardiovascular protection
US pharma major Eli Lilly has announced top-line results from SURPASS-CVOT, a first-of-its-kind head-to-head Phase III cardiovascular outcomes trial comparing two incretin therapies in adults with type 2 diabetes and established atherosclerotic cardiovascular disease.
Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.
A WOMAN has revealed the awful side effects she has experienced when drinking on Mounjaro. Since becoming available on the ...
Ozempic and Mounjaro are both very popular for weight loss at the minute, but there's one big difference between the two ...
Eli Lilly and Company (NYSE:LLY) stock fell on Thursday morning after the pharmaceutical giant’s diabetes drug Mounjaro ...
A YOUNG woman has revealed that in 14 weeks, she has lost three stone on Mounjaro. But although Jess now feels “healthier” ...
"The Mounjaro (tirzepatide) Patient Information Leaflet warns that hair loss is a common side effect in patients treated with ...
Eli Lilly drug Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with the ...
A primary school teacher who weighed 24 stone and was terrified of fitting on a plane said jabs which helped her lose weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback